Therapeutic yield and outcomes of a community teaching hospital code stroke protocol

被引:30
作者
Asimos, AW
Norton, HJ
Price, MF
Cheek, WM
机构
[1] Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28232 USA
[2] Carolinas Med Ctr, Dept Biostat, Charlotte, NC 28232 USA
[3] Carolinas Med Ctr, Inst Neurosci, Charlotte, NC 28232 USA
关键词
cerebrovascular accident; thrombolytic therapy; tissue plasminogen activator; emergency medicine;
D O I
10.1197/j.aem.2003.12.016
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: To describe the experience of a community teaching hospital emergency department (ED) Code Stroke Protocol (CSP) for identifying acute ischemic stroke (AIS) patients and treating them with tissue plasminogen activator (tPA) and to compare outcome measures with those achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial. Methods: This study was a retrospective review from a hospital CSP registry. Results: Over a 56-month period, CSP activation occurred 255 times, with 24% (n = 60) of patients treated with intravenous (IV) tPA. The most common reasons for thrombolytic therapy exclusion were mild or rapidly improving symptoms in 37% (n = 64), intracerebral hemorrhage (ICH) in 23% (n = 39), and unconfirmed symptom onset time for 14% (n = 24) of patients. Within 36 hours of IV tPA treatment, 10% (NINDS = 6%) of patients (n = 6) sustained a symptomatic ICH (SICH). Three months after IV tPA treatment, 60% of patients had achieved an excellent neurologic outcome, based on a Barthel Index of greater than or equal to95 (NINDS = 52%), while mortality measured 12% (NINDS = 17%). Among IV tPA-treated patients, those developing SICH were significantly older and had a significantly higher mean initial glucose value. Treatment protocol violations occurred in 32% of IV tPA-treated patients but were not significantly associated with SICH (Fisher's exact test). Conclusions: Over the study period, the CSP yielded approximately one IV tPA-treated patient for every four screened and, despite prevalent protocol violations, attained three-month functional outcomes equal to those achieved in the NINDS trial. For community teaching hospitals, ED-directed CSPs are a feasible and effective means to screen AIS patients for treatment with thrombolysis.
引用
收藏
页码:361 / 370
页数:10
相关论文
共 45 条
  • [31] TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE
    MARLER, JR
    BROTT, T
    BRODERICK, J
    KOTHARI, R
    ODONOGHUE, M
    BARSAN, W
    TOMSICK, T
    SPILKER, J
    MILLER, R
    SAUERBECK, L
    JARRELL, J
    KELLY, J
    PERKINS, T
    MCDONALD, T
    RORICK, M
    HICKEY, C
    ARMITAGE, J
    PERRY, C
    THALINGER, K
    RHUDE, R
    SCHILL, J
    BECKER, PS
    HEATH, RS
    ADAMS, D
    REED, R
    KLEI, M
    HUGHES, S
    ANTHONY, J
    BAUDENDISTEL, D
    ZADICOFF, C
    RYMER, M
    BETTINGER, I
    LAUBINGER, P
    SCHMERLER, M
    MEIROSE, G
    LYDEN, P
    RAPP, K
    BABCOCK, T
    DAUM, P
    PERSONA, D
    BRODY, M
    JACKSON, C
    LEWIS, S
    LISS, J
    MAHDAVI, Z
    ROTHROCK, J
    TOM, T
    ZWEIFLER, R
    DUNFORD, J
    ZIVIN, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) : 1581 - 1587
  • [32] Early stroke treatment associated with better outcome - The NINDS rt-PA Stroke Study
    Marler, JR
    Tilley, BC
    Lu, M
    Brott, TG
    Lyden, PC
    Grotta, JC
    Broderick, JP
    Levine, SR
    Frankel, MP
    Horowitz, SH
    Haley, EC
    Lewandowski, CA
    Kwiatkowski, TP
    [J]. NEUROLOGY, 2000, 55 (11) : 1649 - 1655
  • [33] MARLER JR, 1997, NIH PUBLICATION
  • [34] Extending tissue plasminogen activator use to community and rural stroke patients
    Merino, JG
    Silver, B
    Wong, E
    Foell, B
    Demaerschalk, B
    Tamayo, A
    Poncha, F
    Hachinski, V
    [J]. STROKE, 2002, 33 (01) : 141 - 146
  • [35] Thrombolytic therapy for acute ischemic stroke: Why the majority of patients remain ineligible for treatment
    O'Connor, RE
    McGraw, P
    Edelsohn, L
    [J]. ANNALS OF EMERGENCY MEDICINE, 1999, 33 (01) : 9 - 14
  • [36] Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals
    Reed, SD
    Cramer, SC
    Blough, DK
    Meyer, K
    Jarvik, JG
    [J]. STROKE, 2001, 32 (08) : 1832 - 1839
  • [37] Stroke incidence among white, black, and Hispanic residents of an urban community - The Northern Manhattan Stroke Study
    Sacco, RL
    Boden-Albala, B
    Gan, R
    Chen, X
    Kargman, DE
    Shea, S
    Paik, MC
    Hauser, VA
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (03) : 259 - 268
  • [38] Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: A retrospective analysis
    Smith, RW
    Scott, PA
    Grant, RJ
    Chudnofsky, CR
    Frederiksen, SM
    [J]. ACADEMIC EMERGENCY MEDICINE, 1999, 6 (06) : 618 - 625
  • [39] Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey
    Tanne, D
    Bates, VE
    Verro, P
    Kasner, SE
    Binder, JR
    Patel, SC
    Mansbach, HH
    Daley, S
    Schultz, LR
    Karanjia, PN
    Scott, P
    Dayno, JM
    Vereczkey-Porter, K
    Benesch, C
    Book, D
    Coplin, WM
    Dulli, D
    Levine, SR
    [J]. NEUROLOGY, 1999, 53 (02) : 424 - 427
  • [40] Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older - The tPA Stroke Survey Experience
    Tanne, D
    Gorman, MJ
    Bates, VE
    Kasner, SE
    Scott, P
    Verro, P
    Binder, JR
    Dayno, JM
    Schultz, LR
    Levine, SR
    [J]. STROKE, 2000, 31 (02) : 370 - 375